Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$6.19
-3.1%
$6.83
$4.25
$9.85
$2.30B0.431.41 million shs3.48 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$17.12
+3.8%
$13.80
$6.36
$35.68
$2.44B1.092.31 million shs1.78 million shs
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
$3.41
+7.2%
$3.41
$1.79
$6.30
$583.10M1.17N/A3,000 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$22.81
+4.2%
$19.90
$10.41
$138.81
$2.23B0.515.65 million shs3.73 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
0.00%+2.15%-4.20%-8.57%-23.36%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.00%+4.52%+36.09%+72.06%-47.10%
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
0.00%0.00%0.00%0.00%-24.89%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.00%+1.33%+28.72%+91.20%-82.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$6.19
-3.1%
$6.83
$4.25
$9.85
$2.30B0.431.41 million shs3.48 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$17.12
+3.8%
$13.80
$6.36
$35.68
$2.44B1.092.31 million shs1.78 million shs
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
$3.41
+7.2%
$3.41
$1.79
$6.30
$583.10M1.17N/A3,000 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$22.81
+4.2%
$19.90
$10.41
$138.81
$2.23B0.515.65 million shs3.73 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
0.00%+2.15%-4.20%-8.57%-23.36%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.00%+4.52%+36.09%+72.06%-47.10%
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
0.00%0.00%0.00%0.00%-24.89%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.00%+1.33%+28.72%+91.20%-82.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
2.00
Hold$9.0045.51% Upside
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2.94
Moderate Buy$34.0798.99% Upside
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
2.00
Hold$1.33-60.90% Downside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.03
Hold$34.4651.07% Upside

Current Analyst Ratings Breakdown

Latest OPT, DYN, BHC, and SRPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/24/2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
10/24/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/22/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetUnderperform$16.00 ➝ $18.00
10/14/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
10/14/2025
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/14/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/10/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperformMarket Perform$13.00
10/10/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformMarket Perform$13.00
10/8/2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
10/8/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Perform$14.00 ➝ $16.00
(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$9.63B0.24$7.73 per share0.80($0.89) per share-6.95
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.19 per shareN/A
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
$30K19,437.00N/AN/A($1.31) per share-2.60
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.90B1.17$2.44 per share9.36$15.99 per share1.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-$46M$0.2623.791.33N/A0.99%-852.36%5.25%10/29/2025 (Estimated)
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%11/11/2025 (Estimated)
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
-$162.79MN/A0.00N/AN/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$235.24M-$0.87N/A2.09N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)

Latest OPT, DYN, BHC, and SRPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2025Q3 2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.81N/AN/AN/AN/AN/A
11/5/2025Q3 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.02N/AN/AN/A$331.51 millionN/A
10/29/2025Q3 2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$1.12N/AN/AN/A$2.61 billionN/A
8/6/2025Q2 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.89$2.02+$1.13$1.89$530.66 million$611.09 million
7/30/2025Q2 2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$0.97$0.90-$0.07$0.40$2.47 billion$2.57 billion
7/28/2025Q2 2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.99-$0.97+$0.02-$0.97N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/AN/AN/AN/AN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
141.90
1.31
0.98
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.17
16.83
16.83
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
N/A
0.22
0.22
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.84
2.89
1.81

Institutional Ownership

CompanyInstitutional Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
78.65%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
55.95%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
19.97%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
14.14%
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
3.20%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20,700370.81 million296.76 millionOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100142.26 million122.15 millionOptionable
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
8171.00 million165.53 millionNot Optionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,37297.71 million90.29 millionOptionable

Recent News About These Companies

Tradr 2X Long SRPT Daily ETF
Sarepta Therapeutics (SRPT) Receives a Buy from Jefferies
What's Going On Sarepta Stock On Wednesday?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bausch Health Cos stock logo

Bausch Health Cos NYSE:BHC

$6.18 -0.20 (-3.06%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$6.24 +0.05 (+0.81%)
As of 10/24/2025 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$17.12 +0.63 (+3.82%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$16.57 -0.56 (-3.24%)
As of 10/24/2025 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Opthea stock logo

Opthea NASDAQ:OPT

$3.41 +0.23 (+7.23%)
As of 10/24/2025 03:30 PM Eastern

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$22.81 +0.92 (+4.20%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$22.80 0.00 (-0.02%)
As of 10/24/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.